Journal of Clinical Immunology

, Volume 33, Issue 1, pp 143–150

Serum Growth Arrest-Specific Protein 6 Levels are a Reliable Biomarker of Disease Activity in Systemic Lupus Erythematosus

  • Hyoun-Ah Kim
  • Jin-Young Nam
  • Ja-Young Jeon
  • Jeong-Mi An
  • Ju-Yang Jung
  • Chang-Bum Bae
  • Chang-Hee Suh
Original Research

DOI: 10.1007/s10875-012-9765-1

Cite this article as:
Kim, H., Nam, J., Jeon, J. et al. J Clin Immunol (2013) 33: 143. doi:10.1007/s10875-012-9765-1

Abstract

Purpose

Growth arrest-specific protein 6 (Gas6) has been suggested to be a biomarker of disease activity in patients with systemic lupus erthematosus (SLE). We investigated the clinical significance of this protein in Korean SLE.

Methods

Blood samples were collected from 150 SLE patients and 50 normal controls (NC). In addition, follow-up samples were collected from 50 SLE patients.

Results

Serum Gas6 levels of SLE patients (43.01 ± 28.02 ng/mL) were higher than those of NC (20.15 ± 9.23 ng/mL, p < 0.001). When evaluated sensitivity and specificity of the Gas6 for diagnosing SLE using ROC curves, the sensitivity and specificity were 72.7 % and 84 % with a cut-off value of 25.3 ng/mL. In the ROC analysis of Gas6, anti-dsDNA antibody, ESR, complement 3 and complement 4 to identify patients with active lupus, area under the curve (AUC) of Gas6 was highest with 0.763. Serum Gas6 levels were significantly higher in the patients with serositis (70.04 ± 30.85 ng/mL) and renal disorder (65.66 ±32.28 ng/mL) compared to those without (41.88 ± 27.44 ng/mL, p = 0.033, 40.3 ± 26.33 ng/mL, p = 0.001, respectively). Gas6 levels were correlated positively with anti-dsDNA antibody (r = 0.199, p = 0.015), ESR (r = 0.204, p = 0.013) and SLEDAI (r = 0.512, p < 0.001). In addition, serum Gas6 levels were correlated negatively with hemoglobin (r = −0.165, p = 0.043), lymphocyte count (r = −0.165, p = 0.043), complement 3 (r = −0.343, p < 0.001) and complement 4 (r = −0.316, p < 0.001). Furthermore, change in serum Gas6 levels was correlated with change in SLEDAI levels in the SLE patients that were followed up (r = 0.524, p < 0.001).

Conclusion

These results suggest that serum Gas6 can be a reliable clinical marker for monitoring disease activity and treatment response in SLE.

Keywords

Growth arrest-specific protein 6systemic lupus erythematosusdisease activitybiomarker

Abbreviations

ACR

American College of Rheumatology

anti-dsDNA

Anti-double stranded DNA

BILAG

British Isles Lupus Assessment Group

ESR

Erythrocyte sedimentation rate

Gas6

Growth arrest-specific protein 6

NC

Normal controls

SLE

Systemic lupus erthematosus

SLEDAI

Systemic lupus erythematosus disease activity index

TBST

0.1 % Tween 20 in TBS

TAM

Tyro-3, Axl and Mer

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Hyoun-Ah Kim
    • 1
  • Jin-Young Nam
    • 1
  • Ja-Young Jeon
    • 1
  • Jeong-Mi An
    • 1
  • Ju-Yang Jung
    • 1
  • Chang-Bum Bae
    • 1
  • Chang-Hee Suh
    • 1
  1. 1.Department of Rheumatology and BK21 Division of Cell Transformation and RestorationAjou University School of MedicineSuwonSouth Korea